HYUNDAI BIOSCIENCE CO., LTD.
Develops antiviral and anticancer drugs using a proprietary drug delivery system.
048410 | KO
Overview
Corporate Details
- ISIN(s):
- KR7048410005
- LEI:
- Country:
- South Korea
- Address:
- 경상북도 김천시 아포읍 아포공단길 106, 김천시
Description
HYUNDAI BIOSCIENCE CO., LTD. is a biotechnology company focused on developing innovative therapeutics using its proprietary drug delivery system (DDS) technology. The company's core science is based on organic-inorganic hybrid technologies designed to safely and effectively deliver active ingredients. Its main development pipeline includes CP-COV03, a broad-spectrum antiviral agent that enhances cellular autophagy to combat viral infections, and Polytaxel, an anticancer drug candidate developed with polymer transfer technologies to reduce toxicity. The company's primary focus is on creating novel treatments for viral diseases and cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2025-12-19 00:00 |
주식등의대량보유상황보고서(일반)
|
Korean | HTML • 113.3 KB | ||
| 2025-12-19 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | HTML • 24.7 KB | ||
| 2025-12-17 00:00 |
주주명부폐쇄기간또는기준일설정
|
Korean | HTML • 4.1 KB | ||
| 2025-09-16 00:00 |
주식등의대량보유상황보고서(일반)
|
Korean | HTML • 113.3 KB | ||
| 2025-09-16 00:00 |
투자판단관련주요경영사항(임상시험계획변경승인신청) (뎅기 또는 뎅기 유사 질환 환자를 대상으로 CPCOV03의 2/3상 …
|
Korean | HTML • 13.7 KB | ||
| 2025-09-08 00:00 |
투자판단관련주요경영사항(임상시험계획변경승인) (전립선암 치료제 CPPCA07의 1상 임상시험계획 변경승인)
|
Korean | HTML • 12.7 KB | ||
| 2025-09-02 00:00 |
투자판단관련주요경영사항(임상시험계획변경승인신청) (전립선암 치료제 CPPCA07의 1상 임상시험계획 변경승인 신청)
|
Korean | HTML • 11.6 KB | ||
| 2025-08-25 00:00 |
[기재정정]사업보고서 (2024.12)
|
Korean | HTML • 1.7 MB | ||
| 2025-08-25 00:00 |
[기재정정]분기보고서 (2025.03)
|
Korean | HTML • 1.2 MB | ||
| 2025-08-25 00:00 |
[기재정정]반기보고서 (2025.06)
|
Korean | HTML • 1.2 MB | ||
| 2025-08-19 00:00 |
주식등의대량보유상황보고서(일반)
|
Korean | HTML • 118.2 KB | ||
| 2025-08-18 00:00 |
투자판단관련주요경영사항(임상시험계획자진취하등) (췌장암 치료제 Polytaxel의 1상 임상시험계획 자진취하)
|
Korean | HTML • 11.1 KB | ||
| 2025-08-14 00:00 |
반기보고서 (2025.06)
|
Korean | HTML • 1.2 MB | ||
| 2025-08-08 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | HTML • 24.4 KB | ||
| 2025-08-01 00:00 |
임시주주총회결과
|
Korean | HTML • 7.5 KB |
Automate Your Workflow. Get a real-time feed of all HYUNDAI BIOSCIENCE CO., LTD. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for HYUNDAI BIOSCIENCE CO., LTD.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for HYUNDAI BIOSCIENCE CO., LTD. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
